证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-099 赛隆药业集团股份有限公司 关于 2025 年度审计会计师事务所辞任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三、风险提示 （一）目前公司正在积极与其他会计师事务所进行沟通，能否及时完成后任 会计师事务所的聘任存在不确定性； （二）根据《深圳证券交易所股票上市规则》第 9.3.12 规定："上市公司 因触及本规则第 9.3.1 条第一款情形，其股票交易被实施退市风险警示后，实际 触及退市风险警示情形相应年度次一年度出现下列情形之一的，本所决定终止其 股票上市交易： 重要内容提示： ●2025 年 12 月 18 日，赛隆药业集团股份有限公司（以下简称"公司"） 收到致同会计师事务所（特殊普通合伙）（以下简称"致同"）发来的《关于辞 任赛隆药业集团股份有限公司 2025 年度财务报告及内部控制审计工作的函》， 因致同 2025 年度审计工作任务繁重、人员变动、其他项目时间安排变化等原因， 鉴于现有人力资源及工作安排的实际情况，预计难以完成公司 2025 年度财务报 告及内部控 ...

Group 1 - The company announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., has received the approval notice for the listing application of the chemical raw material drug, Rabeprazole [1][2] - The approval notice includes details such as the registration number (Y20240000786), acceptance number (CYHS2460643), and the effective period of 12 months [1] - Rabeprazole injection is indicated for the treatment of gastric ulcers and duodenal ulcers when oral therapy is not suitable [2] Group 2 - The approval of Rabeprazole will further enrich the company's raw material drug product pipeline [3] - The production and sales situation will depend on various internal and external environmental changes, indicating a level of uncertainty [3] - The company commits to timely information disclosure based on subsequent developments [3]

Core Viewpoint - *ST Sailong (002898.SZ) has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Rabeprazole, which is indicated for the treatment of bleeding gastric ulcers and duodenal ulcers when oral therapy is not suitable [1] Group 1 - The approval pertains to the injection formulation of Rabeprazole [1] - The drug is specifically aimed at treating conditions that cannot be managed with oral therapies [1]

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-098 赛隆药业集团股份有限公司 关于子公司获得化学原料药上市申请批准通知书 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）全资子公司湖南赛隆药业 有限公司于近日获得国家药品监督管理局核准签发的右兰索拉唑《化学原料药上 市申请批准通知书》，现将相关情况公告如下： 一、原料药基本信息 包装规格：1kg/袋 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 通知书有效期：至 2030 年 12 月 10 日 化学原料药名称：右兰索拉唑 通知书编号：2025YS01099 登记号：Y20240000786 受理号：CYHS2460643 化学原料药注册标准编号：YBY73162025 有效期：12 个月 特此公告。 赛隆药业集团股份有限公司 董事会 2025 年 12 月 13 日 二、其他相关信息 右兰索拉唑注射剂用于 ...

Core Viewpoint - *ST Sailong (002898) has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Rabeprazole, which is indicated for the treatment of bleeding gastric and duodenal ulcers when oral therapy is not suitable [1] Group 1 - The company's wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., has obtained the approval notice for Rabeprazole injection [1] - Rabeprazole injection is specifically used for treating gastric ulcers and duodenal ulcers associated with bleeding [1]

Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Hunan Sailong Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Rulanzoprazole, which is intended for treating bleeding gastric and duodenal ulcers when oral therapy is not suitable [1] Group 1 - The approval notification number for Rulanzoprazole is 2025YS01099, and it is valid until December 10, 2030 [1] - Rulanzoprazole injection will enhance the company’s raw material drug product pipeline [1] - There is uncertainty regarding the production and sales situation, and the company will disclose information as progress occurs [1]

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-097 赛隆药业集团股份有限公司 2025 年第四次临时股东会决议公告 一、会议召开和出席情况 1．会议召开情况 （1）会议召开时间： 现场会议：2025 年 12 月 11 日（星期四）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 12 月 11 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳 证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 12 月 11 日 9： 15-15：00。 （2）会议召开地点：湖南省长沙市长沙县星沙产业基地红枫路 1 号湖南赛 隆药业（长沙）有限公司会议室。 （3）召开方式：以现场投票、网络投票相结合的方式召开。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会无变更、取消、否决议案的情况； 2.本次股东会无变更以往股东会已通过决议的情况。 （4）会议召集人：公司董事会。 （5）会议主持人：董事长殷惠军先生。 （6）会议召开的合法、合 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于赛隆药业集团股份有限公司 2025 年第四次临时股东会的法律意见书 康达股会字【2025】第 500 号 致：赛隆药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）以及《赛隆药业集团股份有限公司章程》（以下简称"《公司章程》"） 的规定，北京市康达律师事务所（以下简称"本所"）接受赛隆 ...

Group 1 - Jianbang Co., Ltd. plans to repurchase shares using self-owned funds between 15 million and 30 million yuan, with a maximum price of 38 yuan per share [1] - Yatong Precision Engineering's investment in a private equity fund has been terminated due to failure to complete the agreed investment, leading to the fund's dissolution [1] - China Storage Co., Ltd. intends to invest 1.129 billion yuan in the Sanjiang Port project, with its wholly-owned subsidiary contributing 500 million yuan to establish a project company [2] Group 2 - Guangxin Co., Ltd. plans to inject assets worth 4.383 billion yuan into its wholly-owned subsidiary, increasing its registered capital from 10 million to 20 million yuan [3] - Jiangxin Home plans to use up to 3 billion yuan of idle self-owned funds for cash management in low-risk financial products [4] - Huangshan Tourism intends to lease part of the Huangshan scenic area for 1.27 billion yuan over a 10-year period [5] Group 3 - Jilin Expressway's general manager has resigned due to work adjustments [6] - Guoyao Modern's subsidiary has received a drug registration certificate for hydromorphone hydrochloride injection, suitable for pain management [8] - Hangya Technology plans to invest up to 70 million USD to establish subsidiaries in Singapore and Malaysia [10] Group 4 - ST Sailong's subsidiary has received approval for the listing of two chemical raw materials [11] - Shanghai Pharmaceuticals' tramadol hydrochloride injection has passed the consistency evaluation for generic drugs [12] - Yubang Electric has obtained a laboratory accreditation certificate from CNAS, indicating its testing capabilities [14] Group 5 - ST Lifang's stock will be subject to delisting risk warning starting December 1 due to administrative penalties [15] - Zhejiang Longsheng is investing 200 million yuan in a private equity partnership focused on high-potential enterprises [15] - Huayang Co., Ltd.'s subsidiary has obtained safety production permits, allowing it to commence production [16] Group 6 - Xujie Electric has won a bid for a State Grid project worth 1.518 billion yuan [17] - Pinggao Electric and its subsidiaries have collectively won a State Grid project worth approximately 773 million yuan [17] - ST Lanhua's subsidiary has entered the trial production phase for a juice beverage project with a total investment of up to 65 million yuan [18] Group 7 - Huakong Saige has terminated its stock issuance plan due to various considerations [19] - Yatong Co., Ltd. plans to invest 36 million yuan to establish a joint venture in renewable energy [20] - Warner Pharmaceuticals has received a drug registration certificate for a new inhalation solution for COPD patients [21] Group 8 - Demais has raised the upper limit for its share repurchase price to 45 yuan per share [22] - China West Electric's subsidiaries have collectively won a State Grid procurement project worth approximately 2.98 billion yuan [22] - Changan Automobile's joint venture has submitted a listing application to the Hong Kong Stock Exchange [23] Group 9 - Yinlun Co., Ltd. plans to invest approximately 133 million yuan to acquire a controlling stake in Shenzhen Deep Blue Electronics [24] - Zhongfu Information intends to increase its wholly-owned subsidiary's capital by 380 million yuan [24] - Financial Street's major shareholder has reduced its stake by 0.25% [25] Group 10 - Audiwei has formally submitted an application for H-share listing [26] - Zhongcai Technology's private placement application has been accepted by the Shenzhen Stock Exchange [27] - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on semiconductor investments [28] Group 11 - Jinkai New Energy is planning to transfer 51% of its subsidiary's equity to introduce strategic investors [31] - Huafeng Technology has reduced its fundraising target for a private placement to no more than 972 million yuan [32] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan [33] Group 12 - Zhongman Petroleum's shareholders plan to reduce their holdings by up to 3% [35] - Innovation New Materials' shareholder intends to reduce their stake by up to 1% [37] - Guangdong Construction has signed a framework agreement to establish a quality testing base in Linzhi Economic Development Zone [39]

*ST赛隆(002898.SZ)公告，公司全资子公司湖南赛隆药业有限公司于近日获得国家药品监督管理局核准 签发的门冬氨酸镁《化学原料药上市申请批准通知书》及门冬氨酸钾《化学原料药上市申请批准通知 书》。化学原料药门冬氨酸钾、门冬氨酸镁可用于生产门冬氨酸钾注射液、门冬氨酸钾镁注射液等制 剂，为电解质补充药物。 ...